The Catalyst Brief
Week of September 28–October 4, 2026
Editor's Note
This week's reporting showed large drugmakers paying for position early. Sanofi committed $1 billion upfront to four Regeneron antibodies, three of them not yet in human studies. Novartis paid $575 million upfront for an mRNA-encoded T cell engager supported by small early datasets. AstraZeneca put $2 billion into Summit before a global Phase 3 readout. AbbVie won an FDA approval that returns a product from its $8.7 billion Cerevel acquisition, and Lilly's amylin combination set up a Phase 3 program. Capital is arriving ahead of the proof, and deal structure is carrying the risk.
Top Stories
Sanofi Pays Regeneron $1 Billion Upfront for Four Early Immunology Antibodies
The Catalyst Brief – October 1, 2026
Summary:
Sanofi will pay Regeneron $1 billion upfront to expand their immunology alliance around four Regeneron-discovered antibodies, with up to $7 billion more in development, regulatory and commercial milestones. Profits are split 50-50. Regeneron leads research and development; Sanofi leads global commercialization. The lead program, REGN20423, is a long-acting IL-13 antibody in Phase 1 for atopic dermatitis. The other three are preclinical and expected to enter human studies next year. Regeneron also holds an option to add Sanofi's lunsekimig once it clears Phase 3 testing in chronic obstructive pulmonary disease. The deal also settles prior litigation between the partners.
Why it matters:
Sanofi is paying heavily for mostly preclinical assets that sit on the same biology as Dupixent, the cornerstone of its business. The structure keeps its next immunology growth cycle inside the Regeneron alliance and closes a dispute that had strained it.
AstraZeneca Invests $2 Billion in Summit Ahead of a Global Phase 3 Readout
The Catalyst Brief – September 29, 2026
Summary:
AstraZeneca is investing $2 billion in Summit Therapeutics, taking a stake of about 12% at a premium to Summit's closing share price. The deal is built around ivonescimab, a PD-1xVEGF bispecific antibody already approved in China for non-small cell lung cancer. The companies will jointly fund trials combining it with sonesitatug vedotin, AstraZeneca's CLDN18.2-directed antibody-drug conjugate, starting in gastrointestinal cancers. A separate nonbinding agreement covers testing ivonescimab with other AstraZeneca medicines, including additional ADCs. Each company retains development and commercial rights to its own molecules, so Summit keeps control of its lead asset.
Why it matters:
AstraZeneca bought exposure, not control, and did so before the readout of HARMONi-3, Summit's global Phase 3 lung cancer trial. Questions persist about whether global studies will replicate the Chinese data, so the timing is itself a signal.
FDA Approves AbbVie's Juvmo for Parkinson's, a Return on Its $8.7 Billion Cerevel Deal
The Catalyst Brief – September 28, 2026
Summary:
On September 28, AbbVie said the FDA approved Juvmo (tavapadon) for adults with Parkinson's disease. The drug came through AbbVie's $8.7 billion acquisition of Cerevel Therapeutics, announced in December 2023 and closed in August 2024. Approval was backed by the Phase 3 TEMPO program. In TEMPO-3, treated patients had significantly more total "on" time, meaning periods of good symptom control, than those on placebo. TEMPO-1 and TEMPO-2 also met their primary endpoints. Emraclidine, the Cerevel deal's most prominent asset, failed mid-stage schizophrenia testing in November 2024.
Why it matters:
Juvmo shows the Cerevel acquisition can still yield a commercial product after its headline program failed. For acquirers, the read-through is that a pipeline bought at a premium can hold value beyond its lead asset, though launch execution now decides how much.
Novartis Commits Up to $7.8 Billion for Abogen's mRNA-Encoded T Cell Engager
The Catalyst Brief – October 2, 2026
Summary:
Novartis struck a deal worth up to $7.8 billion with Suzhou-based Abogen Biosciences for ABO2203, an mRNA candidate that encodes a CD19xCD3 T cell engager. Abogen receives $575 million upfront and up to about $7.2 billion in development, regulatory and commercial milestones, plus royalties. The mRNA is intended to direct a patient's own cells to produce the engager in the body. Abogen argues that gradual exposure could reduce cytokine release syndrome, a common toxicity for the class. Novartis also gets an exclusive option on next-generation assets from Abogen's RNA platform. The human data cited so far are early and small.
Why it matters:
Novartis is paying for a delivery concept as much as a data package: B-cell depletion produced inside the body, not in a factory. The price shows how far large drugmakers will go for China-originated assets before larger studies confirm the early safety signal.
Lilly's Amylin Combination Delivers 23.3% Weight Loss in Type 2 Diabetes
The Catalyst Brief – October 1, 2026
Summary:
Eli Lilly said eloraTZP, which combines the amylin receptor agonist eloralintide with tirzepatide, produced average weight loss of 23.3%, or 54.1 pounds, at 48 weeks at its highest dose. The 367-patient study enrolled adults with obesity or overweight and type 2 diabetes. Tirzepatide 15 mg alone led to an average loss of 34.4 pounds. Adverse events, mainly gastrointestinal, were more frequent with the combination, and discontinuations due to adverse events reached 27% in eloraTZP arms. Lilly plans to begin Phase 3 trials in the fourth quarter of 2026.
Why it matters:
Weight loss is typically attenuated in patients with diabetes, so a 23.3% result strengthens Lilly's position in a harder-to-treat population. The open question is tolerability: Phase 3 has to carry the efficacy forward with fewer dropouts.
ARPA-H Launches SURPASS to Run Faster Trials With Fewer Participants
The Catalyst Brief – October 2, 2026
Summary:
On September 30, the Department of Health and Human Services launched SURPASS, an ARPA-H program meant to evaluate drugs and biologics faster, at lower cost and with fewer participants. A design engine uses digital twins and other predictive models to simulate outcomes before a trial starts. A continuous inference engine analyzes data as it accumulates, reducing the need for large conventional control groups. An operations layer automates trial startup and data tasks. ARPA-H also announced three complementary projects, STACK, COMMONS and CINCH, covering clinical site activation, a national consent architecture and patient-contributed real-world data.
Why it matters:
The program positions AI and simulation as tools that support trial teams' judgment, with the aim of better development efficiency and decision quality. If it gains traction, sponsors may face pressure to justify conventional trial designs.
Market & Investment Pulse
Upfront cash is moving earlier. Sanofi's $1 billion buys four antibodies, three of them preclinical. Novartis's $575 million buys a candidate supported by small early datasets.
Milestones carry most of the headline value. Up to $7 billion of the Sanofi-Regeneron deal and about $7.2 billion of the Novartis-Abogen deal depend on development, regulatory and commercial outcomes.
Equity is an alternative to acquisition. AstraZeneca took about 12% of Summit for $2 billion and will share combination trial costs, while Summit keeps control of ivonescimab.
Acquired pipelines can pay out late. Juvmo's approval gives AbbVie a product from the $8.7 billion Cerevel purchase, after that deal's most prominent asset failed in schizophrenia.
Obesity competition is shifting to combinations. Lilly's eloraTZP posted 23.3% average weight loss in type 2 diabetes, with discontinuations as the variable to address in Phase 3.
Federal policy is targeting trial cost. SURPASS and three companion projects apply simulation, real-time analysis and automation to trial design, site activation and data access.
What to Watch Next Week
Any timing update on HARMONi-3, Summit's global Phase 3 lung cancer trial of ivonescimab.
The first trials combining ivonescimab with AstraZeneca's sonesitatug vedotin in gastrointestinal cancers.
Lilly's Phase 3 start for eloraTZP, planned for the fourth quarter, and how it addresses tolerability.
Juvmo's U.S. launch, including pricing.
Whether larger studies of ABO2203 preserve the early safety signal.
Closing
Every story above draws on The Catalyst Brief's reporting this week. Deal structure, trial design and timing each shaped the probability of success. Read the full analysis at thecatalystbrief.com.
Thank you for reading The Catalyst Brief!
For deeper coverage, explore the full articles linked above. Feel free to forward this brief to colleagues or reply with feedback—your input helps us continue delivering biotech intelligence that improves decision-making and increases the probability of success.